Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	At The Market Offering	Common Stock	Common Stock At The Market Offering	Additional Paid-in Capital	Additional Paid-in Capital At The Market Offering	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2022	$ 499,315		$ 19		$ 1,558,459		$ (4,327)	$ (1,054,836)
Beginning balance (in shares) at Dec. 31, 2022			191,022
Fees incurred related to common stock financings/issuance of common stock from at the market offering	(200)				(200)
Vesting of restricted stock (in shares)			154
Exercise of stock options	331				331
Exercise of stock options (in shares)			233
Stock-based compensation expense	8,751				8,751
Unrealized gain (loss) on marketable securities, net	2,188						2,188
Net income (loss)	(82,123)							(82,123)
Ending balance at Mar. 31, 2023	428,262		$ 19		1,567,341		(2,139)	(1,136,959)
Ending balance (in shares) at Mar. 31, 2023			191,409
Beginning balance at Dec. 31, 2022	499,315		$ 19		1,558,459		(4,327)	(1,054,836)
Beginning balance (in shares) at Dec. 31, 2022			191,022
Net income (loss)	(195,138)
Ending balance at Sep. 30, 2023	365,852		$ 20		1,616,008		(202)	(1,249,974)
Ending balance (in shares) at Sep. 30, 2023			197,064
Beginning balance at Mar. 31, 2023	428,262		$ 19		1,567,341		(2,139)	(1,136,959)
Beginning balance (in shares) at Mar. 31, 2023			191,409
Issuance of common stock, net of offering costs (in shares)				4,586
Issuance of common stock, net of offering costs		$ 27,248		$ 1		$ 27,247
Fees incurred related to common stock financings/issuance of common stock from at the market offering		(985)
Vesting of restricted stock (in shares)			119
Exercise of stock options	691				691
Exercise of stock options (in shares)			357
Issuance of common stock related to employee stock purchase plan	1,705				1,705
Issuance of common stock related to employee stock purchase plan (in shares)			409
Stock-based compensation expense	9,848				9,848
Unrealized gain (loss) on marketable securities, net	1,274						1,274
Net income (loss)	(113,999)							(113,999)
Ending balance at Jun. 30, 2023	355,029		$ 20		1,606,832		(865)	(1,250,958)
Ending balance (in shares) at Jun. 30, 2023			196,880
Fees incurred related to common stock financings/issuance of common stock from at the market offering		(19)				(19)
Vesting of restricted stock (in shares)			81
Exercise of stock options	192				192
Exercise of stock options (in shares)			103
Stock-based compensation expense	9,003				9,003
Unrealized gain (loss) on marketable securities, net	663						663
Net income (loss)	984							984
Ending balance at Sep. 30, 2023	365,852		$ 20		1,616,008		(202)	(1,249,974)
Ending balance (in shares) at Sep. 30, 2023			197,064
Beginning balance at Dec. 31, 2023	$ 287,506		$ 20		1,625,637		(60)	(1,338,091)
Beginning balance (in shares) at Dec. 31, 2023	197,857		197,857
Issuance of common stock, net of offering costs (in shares)			21,773	150
Issuance of common stock, net of offering costs	$ 180,008	1,037	$ 2		180,006	$ 1,037
Fees incurred related to common stock financings/issuance of common stock from at the market offering		$ (113)
Vesting of restricted stock (in shares)			386
Exercise of stock options	4,929				4,929
Exercise of stock options (in shares)			1,120
Stock-based compensation expense	9,092				9,092
Unrealized gain (loss) on marketable securities, net	45						45
Net income (loss)	(107,475)							(107,475)
Ending balance at Mar. 31, 2024	375,142		$ 22		1,820,701		(15)	(1,445,566)
Ending balance (in shares) at Mar. 31, 2024			221,286
Beginning balance at Dec. 31, 2023	$ 287,506		$ 20		1,625,637		(60)	(1,338,091)
Beginning balance (in shares) at Dec. 31, 2023	197,857		197,857
Exercise of stock options (in shares)	2,472
Net income (loss)	$ (217,690)
Ending balance at Sep. 30, 2024	$ 292,478		$ 22		1,848,183		54	(1,555,781)
Ending balance (in shares) at Sep. 30, 2024	223,108		223,108
Beginning balance at Mar. 31, 2024	$ 375,142		$ 22		1,820,701		(15)	(1,445,566)
Beginning balance (in shares) at Mar. 31, 2024			221,286
Fees incurred related to common stock financings/issuance of common stock from at the market offering	(16)				(16)
Vesting of restricted stock (in shares)			52
Exercise of stock options	2,361				2,361
Exercise of stock options (in shares)			548
Issuance of common stock related to employee stock purchase plan	1,077				1,077
Issuance of common stock related to employee stock purchase plan (in shares)			323
Stock-based compensation expense	11,380				11,380
Unrealized gain (loss) on marketable securities, net	(4)						(4)
Net income (loss)	(50,291)							(50,291)
Ending balance at Jun. 30, 2024	339,649		$ 22		1,835,503		(19)	(1,495,857)
Ending balance (in shares) at Jun. 30, 2024			222,209
Fees incurred related to common stock financings/issuance of common stock from at the market offering	(29)				(29)
Vesting of restricted stock (in shares)			84
Exercise of stock options	1,939				1,939
Exercise of stock options (in shares)			815
Stock-based compensation expense	10,770				10,770
Unrealized gain (loss) on marketable securities, net	73						73
Net income (loss)	(59,924)							(59,924)
Ending balance at Sep. 30, 2024	$ 292,478		$ 22		$ 1,848,183		$ 54	$ (1,555,781)
Ending balance (in shares) at Sep. 30, 2024	223,108		223,108